Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An optical coherence tomography study to determine stent coverage in polymer coated versus bare metal rapamycin [sirolimus] eluting stents.

Next Previous
X
Search
Trial Profile

An optical coherence tomography study to determine stent coverage in polymer coated versus bare metal rapamycin [sirolimus] eluting stents.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial infarction
  • Focus Pharmacodynamics

    • Most Recent Events

    • 16 Oct 2009 United Kingdom Clinical Research Network reports accrual to date changed from 82% to 87%.
    • 13 Oct 2009 Planned end date changed from 1 Aug 2007 to 1 Aug 2009 as reported by United Kingdom Clinical Research Network.
    • 13 Oct 2009 New source identified and integrated (United Kingdom Clinical Research Network record no. 4130).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top